USPTO serial 79350987
MYRIAMED
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 7, 2024
- Examiner
- ELLINGER FATHY, JESSICA M
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MYRIAMED?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael A. Whittaker
Michael A. Whittaker Acuity Law Group162 S. Rancho Santa Fe RoadSuite E70-150Encinitas, CA 92024Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science, in particular reagents for cultivation of cells and tissue; cells for research or for scientific purposes, namely, cells, in particular genetically modified cells, human cells and cells derived from induced pluripotent stem cells, in particular cardiomyocytes derived from human induced pluripotent stem cells, skeletal cells derived from human induced pluripotent stem cells, stroma cells derived from human induced pluripotent stem cells, and neuronal cells derived from human induced pluripotent stem cells; biological tissues, other than for medical or veterinary purposes, namely, tissues in particular engineered tissues, in particular tissue comprising cells derived from induced pluripotent stem cells and macroscale muscle tissue, in particular human heart muscle constructed from cardiomyocytes derived from human induced pluripotent stem cells, human skeletal muscle constructed from skeletal cells derived from human induced pluripotent stem cells, human fibrotic tissue constructed from stroma cells derived from human induced pluripotent stem cells, connective tissue constructed from connective tissue cells derived from human induced pluripotent stem cells, brain tissue derived from human induced pluripotent stem cells, and neuronal organoids; biological preparation for use in cell cultures other than for medical or veterinary use; biological tissue cultures, other than for medical or veterinary purposes; biological tissue cultures, other than for medical or veterinary purposes, namely, disease models based on engineered tissue or engineered cells | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations, in particular cells and tissues for treatment of cardiac diseases, degenerative muscular diseases, fibrotic diseases, neurodegenerative diseases, connective tissue diseases or disorders with impaired scaring and wound healing; pharmaceutical preparations for the renewal and regeneration of organs; pharmaceutical preparations for use in cellular therapy; biological tissue derived from stem cells for medical purposes; tissue-regenerative pharmaceutical preparations | ACTIVE | — |
| 009 | Scientific research and laboratory apparatus for drug screening or potency assays; cell culture apparatus for laboratory use, in particular cell culture plates and tissue culture plates for the generation and/or cultivation of engineered tissue | ACTIVE | — |
| 042 | Scientific and industrial research in particular in the biochemical, diagnostic or pharmaceutical fields; biochemical or pharmaceutical laboratory services, in particular in the field of cultivation of cells and tissues; drug discovery services, in particular drug discovery services based on tissue engineered organ platforms; scientific and technological services and research in the field of regenerative medicine; cell culture services for scientific and research purposes, for others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by myriamed GmbH
- Other trademarks owned by myriamed GmbH
- Other trademarks owned by myriamed GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named MYRIAMED
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 23, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 31, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 30, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 7, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 7, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 7, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 25, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 6, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 6, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 4, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 26, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 20, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 7, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 7, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 1, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 1, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 31, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 18, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 11, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 11, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 11, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 25, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 31, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 31, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 12, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 11, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 4, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 30, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 29, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |